Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Medical Genetics

Understanding Niemann-Pick Disease Type C

At a Glance

Niemann-Pick disease type C (NPC) is a rare genetic disorder that causes a toxic buildup of fats and cholesterol in cells. Recently, new FDA-approved medications like Miplyffa and Aqneursa have become available, offering targeted treatments to actively slow down neurological decline.

Receiving a diagnosis of Niemann-Pick Disease Type C (NPC) can feel overwhelming, but you are entering a new era of management for this condition. While NPC is a rare and serious genetic disorder, the landscape of care changed dramatically with the introduction of FDA-approved targeted treatments in 2024 [1]. These breakthroughs offer a new level of hope and a clearer path forward for families and patients navigating this journey.

Understanding the “Storage” Problem

NPC is classified as a lysosomal storage disorder [2]. To understand this, imagine every cell in the body has a recycling center called a lysosome. In a healthy person, lysosomes break down fats and proteins to be reused or discarded. In people with NPC, a “clog” in the system—usually caused by a mutation in the NPC1 or NPC2 genes—prevents cholesterol and other lipids from leaving the cell [3][4].

Instead of being recycled, these fats “store” up inside the cell until they become toxic. Over time, this buildup causes damage to vital organs, particularly the brain, liver, and spleen [1][5].

A New Era of Treatment

For many years, the goal of treatment was primarily managing symptoms. However, the medical community now has new, FDA-approved tools to fight the progression of the disease:

  • Miplyffa (arimoclomol): This is the first drug approved by the FDA specifically to treat the neurological symptoms of NPC [1]. It is taken orally and is approved for adults and children aged 2 and older, typically used in combination with another medication called miglustat [1][6].
  • Aqneursa (levacetylleucine): This medication (also known as N-acetyl-L-leucine) has shown the ability to improve neurological symptoms, such as balance and speech, in clinical trials [7][8].

These approvals represent a shift from “waiting and seeing” to active, targeted intervention aimed at slowing the decline of motor skills and cognitive function [1].

Disease Trajectory and Symptoms

NPC is often called a “spectrum” disease because it looks different for everyone. Its progression is usually grouped by the age when symptoms first appear:

Onset Type Typical Age Primary Signs
Early Infantile Under 2 years Jaundice, enlarged liver or spleen, delayed motor milestones [9][5]
Late Infantile/Juvenile 2 to 15 years Clumsiness (ataxia), speech difficulties, and Vertical Supranuclear Gaze Palsy (difficulty looking up and down) [10][11]
Adult Over 15 years Psychiatric symptoms (like depression or psychosis), cognitive decline, and movement disorders [12][10]

One of the most characteristic signs of NPC is Vertical Supranuclear Gaze Palsy (VSGP), which is an inability to move the eyes quickly up and down [10]. Identifying this sign early is often the key to getting a faster diagnosis [11].

Incidence and Outlook

NPC is an “ultra-orphan” disease, meaning it is extremely rare. It is estimated to occur in approximately 1 in 100,000 to 120,000 live births [9]. Because symptoms can be vague or mimic other conditions, many experts believe it may be more common but frequently misdiagnosed [13][14].

While the disease is progressive, the combination of early diagnosis, newer treatments, and established supportive care (like miglustat) is helping patients maintain their independence and quality of life for longer than was previously possible [15][1]. Clinical guidelines now emphasize a “shared-care” model, where your local doctor works closely with specialized NPC centers to ensure you have access to the latest research and therapies [16][17].

Common questions in this guide

What causes Niemann-Pick disease type C?
NPC is caused by a genetic mutation, most commonly in the NPC1 or NPC2 genes. These mutations create a 'clog' in the cell's recycling center, preventing it from properly processing cholesterol and other fats, which then build up to toxic levels.
What is Vertical Supranuclear Gaze Palsy (VSGP)?
VSGP is a hallmark symptom of Niemann-Pick disease type C where a person loses the ability to move their eyes quickly up and down. Identifying this specific eye movement issue early is often a key step in getting an accurate and timely diagnosis.
Are there FDA-approved treatments for NPC?
Yes, the FDA recently approved new targeted treatments for NPC, including Miplyffa (arimoclomol) and Aqneursa (levacetylleucine). These medications represent a major shift in care, aiming to actively slow the decline of motor skills and cognitive function.
What are the symptoms of Niemann-Pick type C?
NPC is a progressive spectrum disease, and symptoms depend heavily on the age they first appear. Infants often develop jaundice and enlarged organs, children typically experience clumsiness and speech issues, and adults may face cognitive decline and psychiatric symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific genetic mutation was identified in my (or my child's) case—NPC1 or NPC2?
  2. 2.Given the recent FDA approvals, is a combination therapy appropriate for us?
  3. 3.How do you plan to monitor disease progression using the NPC Clinical Severity Scale?
  4. 4.Does our local hospital have a shared-care arrangement with a Niemann-Pick center of excellence?
  5. 5.What baseline neurological and visceral (organ) assessments should we perform immediately?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Arimoclomol: First Approval.

    Keam SJ

    Drugs 2025; (85(1)):111-116 doi:10.1007/s40265-024-02129-x.

    PMID: 39715913
  2. 2

    [Niemann-Pick type C disease in a child].

    Novikova ES, Kotov AS, Kotalevskaya YY, et al.

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2017; (117(11. Vyp. 2)):62-66 doi:10.17116/jnevro201711711262-66.

    PMID: 29359721
  3. 3

    Structural Insight into Eukaryotic Sterol Transport through Niemann-Pick Type C Proteins.

    Winkler MBL, Kidmose RT, Szomek M, et al.

    Cell 2019; (179(2)):485-497.e18 doi:10.1016/j.cell.2019.08.038.

    PMID: 31543266
  4. 4

    NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress.

    Höglinger D, Burgoyne T, Sanchez-Heras E, et al.

    Nature communications 2019; (10(1)):4276 doi:10.1038/s41467-019-12152-2.

    PMID: 31537798
  5. 5

    A phase 1/2 open label nonrandomized clinical trial of intravenous 2-hydroxypropyl-β-cyclodextrin for acute liver disease in infants with Niemann-Pick C1.

    Reynolds M, Linneman LA, Luna S, et al.

    Molecular genetics and metabolism reports 2021; (28()):100772 doi:10.1016/j.ymgmr.2021.100772.

    PMID: 34113546
  6. 6

    Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.

    Mengel E, Patterson MC, Da Riol RM, et al.

    Journal of inherited metabolic disease 2021; (44(6)):1463-1480 doi:10.1002/jimd.12428.

    PMID: 34418116
  7. 7

    Current and emerging therapeutic advancements for Niemann-Pick disease type C: where are we now and what does the future hold?

    Hahn A

    Expert review of neurotherapeutics 2026; (26(6)):539-545 doi:10.1080/14737175.2026.2661657.

    PMID: 42007957
  8. 8

    ORMDL mislocalization by impaired autophagy in Niemann-Pick type C disease leads to increased de novo sphingolipid biosynthesis.

    Brown RDR, Mahawar U, Wattenberg BW, Spiegel S

    Journal of lipid research 2024; (65(6)):100556 doi:10.1016/j.jlr.2024.100556.

    PMID: 38719150
  9. 9

    Laboratory diagnosis of the Niemann-Pick type C disease: an inherited neurodegenerative disorder of cholesterol metabolism.

    Sitarska D, Ługowska A

    Metabolic brain disease 2019; (34(5)):1253-1260 doi:10.1007/s11011-019-00445-w.

    PMID: 31197681
  10. 10

    Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life.

    Wu M, Ceponiene R, Bayram E, Litvan I

    Movement disorders clinical practice 2020; (7(8)):961-964 doi:10.1002/mdc3.13085.

    PMID: 33163568
  11. 11

    Abnormal Vertical Eye Movements as a Clue for Diagnosis of Niemann-Pick Type C.

    Gupta DK, Blanco-Palmero VA, Chung WK, Kuo SH

    Tremor and other hyperkinetic movements (New York, N.Y.) 2018; (8()):560 doi:10.7916/D8XS7BGD.

    PMID: 29971198
  12. 12

    [Psychiatric disorders in adult form of Niemann-Pick disease type C].

    Maubert A, Hanon C, Sedel F

    L'Encephale 2016; (42(3)):208-13.

    PMID: 26727648
  13. 13

    The hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease.

    Hendriksz CJ, Anheim M, Bauer P, et al.

    Current medical research and opinion 2017; (33(5)):877-890 doi:10.1080/03007995.2017.1294054.

    PMID: 28276873
  14. 14

    Niemann-Pick type C: focus on the adolescent/adult onset form.

    Di Lazzaro V, Marano M, Florio L, De Santis S

    The International journal of neuroscience 2016; (126(11)):963-71 doi:10.3109/00207454.2016.1161623.

    PMID: 26998855
  15. 15

    Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study.

    Patterson MC, Garver WS, Giugliani R, et al.

    Journal of inherited metabolic disease 2020; (43(5)):1060-1069 doi:10.1002/jimd.12245.

    PMID: 32324281
  16. 16

    Consensus clinical management guidelines for Niemann-Pick disease type C.

    Geberhiwot T, Moro A, Dardis A, et al.

    Orphanet journal of rare diseases 2018; (13(1)):50 doi:10.1186/s13023-018-0785-7.

    PMID: 29625568
  17. 17

    An Australian standard of care for Niemann-Pick disease type C.

    Tchan M, Smith N, Peters H, et al.

    Internal medicine journal 2026; (56(5)):832-848 doi:10.1111/imj.70370.

    PMID: 41824299

This page provides educational information about Niemann-Pick Disease Type C and new treatment options. It does not replace professional medical advice from a specialized neurologist or geneticist.

Get notified when new evidence is published on Niemann-Pick disease type C.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.